Research programme: protein kinase C-delta inhibitor therapeutics - BriaCell Therapeutics

Drug Profile

Research programme: protein kinase C-delta inhibitor therapeutics - BriaCell Therapeutics

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sapientia Pharmaceuticals
  • Developer BriaCell Therapeutics Corp
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action Protein kinase C delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Systemic scleroderma

Most Recent Events

  • 24 Jul 2017 Sapientia announces intention to submit IND to US FDA within 2 years (Sapientia Pharmaceuticals Pipeline, July 2017)
  • 24 Jul 2017 Sapientia Pharmaceuticals has been acquired and merged into BriaCell Therapeutics Corp
  • 24 Jul 2017 Sapientia Pharmaceuticals has patent protection for protein kinase C-delta inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top